Prospects for a Grail IPO remain unclear. The biotech filed to go public last fall, but it struck a deal to be acquired by Illumina (ILMN) for $8 billion instead. As of mid-2021, regulators were still reviewing the deal for approval.
While the merger is still unclear, shares of Illumina are currently available for purchase.
Latest updates
December 16: Illumina has criticized EU regulators in court for the Commission’s scrutiny of its acquisition of Grail.
August 18: US biotech company Illumina acquires Grail, even though the European Commission has not completed its review of the acquisition.
April 20: In response to competition concerns, EU antitrust regulators will examine Illumina’s proposed acquisition of Grail.
March 30: The Federal Trade Commission has filed to block Illumina’s proposed acquisition of Grail.
How to buy shares in Illumina
If Grail goes public independently, you’ll be able to buy shares after the IPO happens. You can also buy shares of Illumina now — though it’s unclear whether Illumina’s acquisition of Grail will hold.
- Compare share trading platforms. Use our comparison table to find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol and research it before deciding if it’s a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches your desired price.
Finder's picks for buying Grail stock when it goes public
Best for beginners
Go to site
- No-cost financial planning and automated investing
- $0 commission on stocks, ETFs and options
- Get up to $1,000 in stock when you fund a new account within 30 days
Best for options trading
Go to site
- Trade options, futures, options on futures, stocks, ETFs
- $0 commission to close options
- Get $100-$5,000 when you open an account with $5,000 to $1,000,000+
Best for alternative investments
Go to site
- Trade stocks, bonds, options, ETFs, crypto, Treasurys, collectibles, royalties
- AI-powered analysis tools
- Get up to $10,000 cash when you transfer your account to Public
What we know about the Grail IPO
Grail filed a registration form with the US Securities and Exchange Commission (SEC) to go public on the Nasdaq Global Select Market under the ticker symbol GRAL. Not yet an official IPO, this is one of the first steps of taking a private company public.
The exact IPO date has not been announced. There's no news yet about how much the stock will cost when it goes public. We'll update this page with more information as it becomes available.
How do similar companies perform?
It's impossible to predict how any stock will perform — and IPOs can be particularly volatile. Looking at the performance of similar companies can help you decide if now is a good time to buy Grail stock.
See how the following stocks are performing, and view details like market capitalization, the price-to-earnings (P/E) ratio, price/earnings-to-growth (PEG) ratio and dividend yield.
-
Company summary
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Historical performance
Stock information
- Market capitalization: $252586240
- PEG ratio: 0
- Dividend yield: N/A%
Get more detailed information and learn how to buy QURE.US stock
-
Company summary
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. It offers ROLVEDON(Eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. The company develops Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and license agreement with Therapyx, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Boston, Massachusetts. As of July 31, 2023, Spectrum Pharmaceuticals, Inc. operates as a subsidiary of Assertio Holdings, Inc.
Historical performance
Stock information
- Market capitalization: $211403376
- PEG ratio: 0
- Dividend yield: 0%
Get more detailed information and learn how to buy SPPI.US stock
-
Company summary
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for patients treated with rivaroxaban or apixaban. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG, NMOSD, ALS, COVID-19, and HSCT-TMA; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1820 that is in Phase I clinical trial, a therapeutic antagonist of properdin; and ALXN1720, which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; ALXN1830, which are in Phase I clinical trials for neonatal Fc receptor; ALXN2040 and ALXN2050 to treat diseases associated with dysregulation of the complement alternative pathway; ALXN1850, an enzyme replacement therapy; ALXN2060 for treating transthyretin amyloidosis; and ALXN2075 for treatment of relapsed/refractory chronic lymphocytic leukemia. The company serves distributors, pharmacies, hospital, hospital buying groups, and other healthcare providers in the United States and internationally. The company was incorporated in 1992 and is based in Boston, Massachusetts with an additional office in Switzerland. As of July 21, 2021, Alexion Pharmaceuticals, Inc. operates as a subsidiary of AstraZeneca PLC.
Historical performance
Stock information
- Market capitalization: $40335970304
- P/E ratio: 59.234
- PEG ratio: 1.1706
- Dividend yield: 0%
Get more detailed information and learn how to buy ALXN.US stock
Compare trading platforms
Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 5 of 5
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
